Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purposes only and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for securities of Guanze Medical Information Industry (Holding) Co., Ltd. or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of Guanze Medical Information Industry (Holding) Co., Ltd. in any jurisdiction in contravention of applicable laws or regulations. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
富德(香港)投資控股有限公司
(Incorporated in Hong Kong with limited liability)

GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD.
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2427)

CLARIFICATION ANNOUNCEMENT IN RELATION TO ANNOUNCEMENT MADE PURSUANT TO RULE 3.5 OF THE TAKEOVERS CODE

Reference is made to the announcement jointly issued by Guanze Medical Information Industry (Holding) Co., Ltd. (the "**Company**") and FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (the "**Offeror**") dated 11 February 2026 (the "**Rule 3.5 Announcement**"). Unless otherwise defined herein, all capitalised terms used herein shall have the same meanings as defined in the Rule 3.5 Announcement.

The Company and the Offeror would like to replace the paragraphs under the section headed "PUBLIC FLOAT AND MAINTENANCE OF THE LISTING STATUS OF THE COMPANY" in the Rule 3.5 Announcement with the following paragraphs:

"PUBLIC FLOAT AND MAINTENANCE OF THE LISTING STATUS OF THE COMPANY

Pursuant to the Listing Rules, the Stock Exchange has stated that

(a) if, at the close of the Offer, the Stock Exchange believes that:

(i) a false market exists or may exist in the trading of the Shares; or

(ii) an orderly market does not exist or may not exist;

it will consider exercising its discretion to suspend dealings in the Shares; and

(b) if, at the close of the offer, the Company has a Significant Public Float Shortfall (as defined in Rule 13.32F of the Listing Rules), then:

(i) the Stock Exchange will add a designated marker to the stock name of the Shares; and

(ii) the Stock Exchange will cancel the listing of the Shares if the Company fails to re-comply with Rule 13.32B of the Listing Rules for a continuous period of 18 months from the commencement of the Significant Public Float Shortfall.

Therefore, it should be noted that upon close of the Offer, there may be insufficient public float of the Shares and the trading in the Shares may be suspended until sufficient public float exists for the Shares.

The Company will make an application to the Stock Exchange for a temporary waiver from strict compliance with Rule 8.08(1)(a) of the Listing Rules in case less than 25% of the issued share capital of the Company will be held by the public upon the close of the Offer in accordance with Rule 13.33 of the Listing Rules. Appropriate steps will be taken to ensure public float will be restored as soon as possible after the close of the Offer. The steps that the Offeror may take include but not limited to placing down or selling sufficient number of accepted Shares which it will acquire from the Offer to selected Independent Third Parties, whom will also not be acting in concert with the Offeror, its ultimate beneficial owners and parties acting in concert with any of them, or in the market. No arrangements have been confirmed or put in place as at the date of this joint announcement.

Further announcement(s) regarding the restoration of public float will be made by the Company as and when appropriate.

The Offeror intends the Company to remain listed on the Stock Exchange following the close of the Offer. Each of the sole director of the Offeror and the Directors will jointly and severally undertake to the Stock Exchange that if, at the close of the Offer, the Company fails to comply with the requirement of Rule 13.32B of the Listing Rules, they will take appropriate steps to ensure the Company's compliance with Rule 13.32B of the Listing Rules at the earliest possible moment."

Save as disclosed above, all other information and contents contained in the Rule 3.5 Announcement remain unchanged. This announcement is supplemental to the Rule 3.5 Announcement and should be read in conjunction with Rule 3.5 Announcement.

By order of the board
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
Zhang, David Jia-yuan
Sole director

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman and executive Director

Hong Kong, 20 February 2026

As at the date of this joint announcement, Mr. Zhang is the sole director of the Offeror. As at the date of this joint announcement, Mr. Cheung is the sole director of Shenzhen City Junde Investment Co., Ltd. (*深圳市峻德投資有限公司*), the ultimate parent company of the Offeror.*

Each of the sole director of the Offeror (being Mr. Zhang) and the sole director of the ultimate parent company of the Offeror (being Mr. Cheung) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Group, the Selling Shareholder and its ultimate beneficial owner), and confirms, having made all reasonable enquires, that to the best of his knowledge, opinions expressed in this joint announcement (other than those expressed by the Directors in their capacities as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Board comprises Mr. Meng Xianzhen (Chairman) and Mr. Guo Zhenyu as executive Directors, Ms. Meng Cathy as non-executive Director, and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them), and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by each of the sole director of the Offeror and the sole director of the ultimate parent company of the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

In the event of any inconsistency, the English text of this joint announcement shall prevail over its Chinese text.